Action I-mab (IMAB)
Entreprise du secteur de la santé. Voici le cours, un aperçu de l'activité et l'essentiel à savoir sur I-mab en septembre 2026.
I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.
Performance de croissance sur six mois
Aperçu de la performance de l'action
Note des analystes
Analysts strongly recommend buying I-Mab's stock with a target price of $21.43, indicating significant growth potential.
Santé financière
I-Mab has a moderate financial standing with decent cash flow and book value per share.
Voyez plus d'actions en téléchargeant l'application GRATUITEMENT
Cela ne prend que 60 secondes.
Pourquoi investir avec Nemo ?
Zéro commission
Négociez actions, ETF et plus encore sans commission. Gardez une plus grande part de vos gains.
Fiable et réglementé
Membre du groupe Exinity depuis 2015, au service de plus d'un million de clients dans le monde.